Longtime Partner Proud to Sponsor the 2025 San Diego Walk and 2024 Community Summit
SAN DIEGO, April 15, 2025 — ProSciento, Inc., a leading clinical research organization focused on metabolic diseases, proudly celebrates 18 years of continuous support for Breakthrough T1D—formerly known as JDRF—and is honored to sponsor two events this year: the Community Summit in San Diego on May 17, 2025 and the Breakthrough T1D San Diego Walk on November 2, 2025.
Since 2007, ProSciento has partnered with Breakthrough T1D through ongoing participation in its cornerstone events, including the annual Walk, Community Summit, and Gala. Over the past 18 years, ProSciento has contributed more than $110,000 through fundraising and sponsorship efforts—underscoring a lasting commitment to advancing type 1 diabetes (T1D) research and supporting the T1D community.
“We’re proud to stand alongside Breakthrough T1D in the fight against diabetes,” said Dr. Marcus Hompesch, CEO of ProSciento. “Our work in advancing clinical research for metabolic diseases gives us a deep appreciation for the importance of innovation, advocacy, and community in driving change. Supporting events like the Walk and Community Summit isn’t just about sponsorship—it’s about being part of a movement to accelerate progress toward a cure and better lives for millions affected by T1D.”
The Breakthrough T1D Community Summit on May 17, 2025, at the Liberty Station Conference Center, will bring together individuals and families impacted by T1D for a day of education, connection, and inspiration. For more information, visit prosciento.com/breakthrough-t1d-summit-2025/.
Registration for the 2025 San Diego Walk is also now open at walk.breakthrought1d.org/sandiego. ProSciento looks forward to walking alongside families, advocates, and fellow supporters this fall in support of a cure.
About ProSciento
ProSciento is the leading provider of clinical research and patient engagement solutions for metabolic continuum diseases with unparalleled expertise in diabetes, obesity, and steatotic liver disease. As a full-service clinical research organization (CRO), ProSciento works with clients of all sizes worldwide to design and conduct multinational clinical trials, from early clinical development planning through phase III. With two decades as a leading scientific contributor to metabolic continuum research, ProSciento has trusted relationships with clients, partners, and patients, supporting the development of therapeutics and devices that make an important difference in the lives of individuals with metabolic diseases. For more information, please visit www.prosciento.com.